Sign up Australia
Proactive Investors - Run By Investors For Investors

Novogen raises funds to progress cancer drugs to the clinic

Novogen raises funds to progress cancer drugs to the clinic

Novogen (ASX:NRT) has raised $1,795,000 through its ASX bookbuild capital raising priced at $0.11 per share to progress its programs and consider a range of other funding offers.

The company also expects to soon receive a $1.45 million research and development tax rebate.

In August, the company received shareholder approval to issue 80 million shares and 80 million options.

The ASX bookbuild was conducted on this basis, resulting in the issue of 16,318,184 shares.

Each share comes with an attached 1 year unlisted options with an exercise price of $0.125.

Novogen has developed four new chemotherapy drugs and is now focused on bringing them into the clinic.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full NRT profile View Profile

Novogen Ltd Timeline

Newswire
August 05 2015

Related Articles

test tubes filled with blood
November 03 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use